IDT Australia announces board shake-up
CMO IDT Australia (ASX:IDT) has announced a board reshuffle to support a planned expansion drive.
The company revealed that Alan Blackman and Robert Burnet - both of whom have been serving on the board for 27 years - will step down as directors at the end of June.
Reo Shigeno, CEO of Japanese clinical trial site management company I’rom Holdings’ Australian subsidiary, will join the board as a non-executive director. I’rom Holdings this month acquired an 18.8% stake in IDT Australia for $2 million in shares.
Also joining the board will be Australian biotechnology veteran Graeme Kaufman. A long-time former CSL executive, Kaufman is currently chairman of Bionomics (ASX:BNO) and a director at Cellmid (ASX:CMD).
IDT chairman and founder Dr Graeme Blackman will meanwhile step aside from the role during calendar Q3. A replacement will be selected in the interim.
The board shake-up comes one month after IDT appointed Dr Paul MacLeman as its new CEO. Prior to joining IDT Australia, MacLeman was most recently CEO of Genetic Technologies (ASX:GTG).
IDT Australia shares were trading unchanged at $0.25 as of around 1 pm on Thursday.
Cancer drug eliminates bone metastasis in lab models
Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...
TGA rejects Alzheimer's drug due to safety concerns
The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
